Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586515 · ClinicalTrials.gov registry record · Phase 1
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 630
- Enrollment target
- 20
- Study locations
NCT06586515 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 630 participants, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT06586515, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 630 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Cetuximab
- DRUG Gemcitabine
- DRUG nab-paclitaxel
- DRUG LY3962673
Study Locations (20)
Tennessee
- Sarah Cannon Research Institute - Nashville
- USO - US Oncology Research Network - Nashville
- Vanderbilt University School of Medicine - Nashville
California
- City of Hope - Duarte
- University of California, Los Angeles (UCLA) - Los Angeles
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
- South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids
New York
- New York University (NYU) Langone Medical Center - New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
Ohio
- University of Cincinnati (UC) - Cancer Institute - Cincinnati
- Cleveland Clinic - Cleveland
Colorado
- Sarah Cannon Research Institute at HealthOne - Denver
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 2024-09-12 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06586515
The ClinicalTrials.gov registry entry for NCT06586515 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Oxaliplatin is the first listed.
NCT06586515 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Tennessee, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06586515 about?
NCT06586515 is a clinical study titled "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors". The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
What is the current status of trial NCT06586515?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 630 participants. The study started on 2024-09-12. Estimated completion is 2029-03.
What conditions does trial NCT06586515 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT06586515?
The interventions under investigation include: Oxaliplatin (DRUG), Cetuximab (DRUG), Gemcitabine (DRUG), nab-paclitaxel (DRUG), LY3962673 (DRUG).
Who is sponsoring clinical trial NCT06586515?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586515 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.